In recent years, conjugate drugs have developed into one of
the hot tracks in the pharmaceutical industry.
Analysts said that compared with the current ADC drugs, PDC drugs have the characteristics of small molecular weight, strong tumor penetration, low immunogenicity, large-scale synthesis by solid-phase synthesis, low production cost, and relatively good pharmacokinetics, etc.
, and have become the next generation of targeted anti-tumor drugs after small molecule targeted drugs
, monoclonal antibodies and ADCs.
Over $3.
3 billion in 4 days! Recently, pharmaceutical giants have frequently cooperated with PeptiDream to develop peptide conjugate drugs, which has attracted market attention
.
It is understood that recently, PeptiDream announced that it has entered into cooperation and licensing agreements with Merck and Eli Lilly respectively to discover and develop novel peptide conjugates (PDCs) targeting multiple drug targets, with a total amount of more than $3.
3 billion.
On December 26, 2022, PeptiDream announced that it has entered into a partnership with Eli Lilly to jointly develop novel peptide-conjugate drugs (PDCs).
The two companies will utilize a proprietary drug discovery and development platform, PDPS (Peptide Discovery Platform System), to deliver payloads to target cells and tissues to identify unique cyclic peptides
with binding properties.
PeptiDream was responsible for creating and optimizing the peptide, and Eli Lilly was responsible for creating and optimizing the payload and covering the development costs
of PDC products based on this collaborative research.
Under the terms of the agreement, PeptiDream will receive an upfront payment from Eli Lilly and is expected to receive development, approval and marketing milestone fees totaling up to US$1.
235 billion (approximately 163 billion yen), as well as royalties
based on post-commercialization sales.
It is reported that Eli Lilly has a long-term cooperative relationship
with PeptiDream.
In December 2013, the two companies signed the first collaboration agreement to jointly develop cyclic peptide drug
candidates.
In March 2016, Eli Lilly obtained a non-exclusive license for PDPS technology, which expressly excludes work on
the PDC project.
This cooperation is the third cooperation
between Eli Lilly and PeptiDream.
In addition to the partnership with Eli Lilly, on December 22, PeptiDream and Merck announced that they have entered into a new multi-target collaboration and license agreement (after a long-standing relationship).
Under the agreement, PeptiDream will provide peptide candidate identified from its proprietary Peptide Discovery Platform System (PDPS) technology for use in the development of PDCs
for targets of interest by Merck.
Merck will have exclusive rights to peptide candidate binding to cytotoxic payloads and will be responsible for all development
of collaborative PDC products.
Under the terms, PeptiDream will receive an advance payment from Merck and will be eligible to receive milestone payments based on the achievement of certain developmental, regulatory and commercial milestones, which could total up to $2.
1 billion
.
In addition, PeptiDream is eligible for royalties
on net sales of any such products.
It is understood that PeptiDream aims to meet unmet medical needs and improve the quality of life
of people around the world by producing new innovative drugs with special cyclic peptides.
Since its inception in 2006, the company has generated a trillion-dollar peptide library based on a unique drug discovery and development platform from which promising and highly selective non-standard cyclic peptides
have been efficiently screened.
Using PDPS (Peptide Discovery Platform System) technology, PeptiDream facilitates peptide drug discovery, small molecule drug discovery, and the development
of therapeutic and diagnostic drugs using peptide-drug conjugates (PDCs).
PDC, as the focus of PeptiDream's layout, has a number of projects under development
.
Among them, the targets involved in the layout of PDC include PD-L1, CD38, TfR, c-Met, etc
.
At present, it has cooperated with a number of multinational pharmaceutical companies, including Eli Lilly, Merck Sharp & Dohme, Roche, Novartis, Johnson & Johnson, Shionogi and so on
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
